Transduction Efficiencies of Novel AAV Vectors in Mouse Airway Epithelium In Vivo and Human Ciliated Airway Epithelium In Vitro

被引:139
作者
Limberis, Maria P. [1 ]
Vandenberghe, Luk H. [1 ]
Zhang, Liqun [2 ,3 ]
Pickles, Raymond J. [2 ,3 ]
Wilson, James M. [1 ]
机构
[1] Univ Penn, Dept Pathol & Lab Med, Gene Therapy Program, Philadelphia, PA 19104 USA
[2] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA
关键词
RECOMBINANT ADENOASSOCIATED VIRUS; CYSTIC-FIBROSIS PATIENTS; GENE-TRANSFER; MAXILLARY SINUS; BIOLOGICAL EFFICACY; HEPARIN-BINDING; PHASE-I; LUNG; THERAPY; CELLS;
D O I
10.1038/mt.2008.261
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have characterized the ability of adeno-associated virus (AAV) serotypes 1-9 in addition to nineteen novel vectors isolated from various tissues, to transduce mouse and human ciliated airway epithelium (HAE). Vectors expressing alpha-1-antitrypsin (AAT) and beta-galactosidase were co-instilled into the mouse lung. Of all the vectors tested rh. 64R1, AAV5 and AAV6 were the most efficient. The high transduction observed in mouse was reproduced in HAE cell cultures for both rh. 64R1 and AAV6 but not for AAV5. Since AAV6 was the most efficient vector in mouse and HAE we also tested the transduction efficiencies of the AAV6 singleton vectors (i.e., AAV6 variants with targeted mutations) in these models. Of these, AAV6.2 transduced mouse airway epithelium and HAE with greater efficiency than all other AAV vectors tested. We demonstrated that AAV6.2 exhibits improved transduction efficiency compared to previously reported AAVs in mouse airways and in culture models of human airway epithelium and that this vector requires further development for preclinical and clinical testing.
引用
收藏
页码:294 / 301
页数:8
相关论文
共 40 条
[1]   A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease [J].
Aitken, ML ;
Moss, RB ;
Waltz, DA ;
Dovey, ME ;
Tonelli, MR ;
McNamara, SC ;
Gibson, RL ;
Ramsey, BW ;
Carter, BJ ;
Reynolds, TC .
HUMAN GENE THERAPY, 2001, 12 (15) :1907-1916
[2]  
Aneja MK, 2006, CURR OPIN MOL THER, V8, P432
[3]   Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins [J].
Auricchio, A ;
O'Connor, E ;
Weiner, D ;
Gao, GP ;
Hildinger, M ;
Wang, LL ;
Calcedo, R ;
Wilson, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (04) :499-504
[4]   Adeno-associated virus and the development of adeno-associated virus vectors: A historical perspective [J].
Carter, BJ .
MOLECULAR THERAPY, 2004, 10 (06) :981-989
[5]  
Conrad CK, 1996, GENE THER, V3, P658
[6]   The promise of gene therapy for the treatment of α-1 antitrypsin deficiency [J].
Cruz, Pedro E. ;
Mueller, Christian ;
Flotte, Terence R. .
PHARMACOGENOMICS, 2007, 8 (09) :1191-1198
[7]   Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue [J].
Duan, DS ;
Sharma, P ;
Yang, JS ;
Yue, YP ;
Dudus, L ;
Zhang, YL ;
Fisher, KJ ;
Engelhardt, JF .
JOURNAL OF VIROLOGY, 1998, 72 (11) :8568-8577
[8]   ADENOVIRUS-MEDIATED TRANSFER OF THE CFTR GENE TO LUNG OF NONHUMAN-PRIMATES - BIOLOGICAL EFFICACY STUDY [J].
ENGELHARDT, JF ;
SIMON, RH ;
YANG, YP ;
ZEPEDA, M ;
WEBERPENDLETON, S ;
DORANZ, B ;
GROSSMAN, M ;
WILSON, JM .
HUMAN GENE THERAPY, 1993, 4 (06) :759-769
[9]   Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques [J].
Fischer, AC ;
Beck, SE ;
Smith, CI ;
Laube, BL ;
Askin, FB ;
Guggino, SE ;
Adams, RJ ;
Flotte, TR ;
Guggino, WB .
MOLECULAR THERAPY, 2003, 8 (06) :918-926
[10]   Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis [J].
Flotte, Terence R. ;
Ng, Philip ;
Dylla, Doug E. ;
McCray, Paul B., Jr. ;
Wang, Guoshun ;
Kolls, Jay K. ;
Hu, Jim .
MOLECULAR THERAPY, 2007, 15 (02) :229-241